DCM
PRVB

DAFNA Capital Management’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

DAFNA Capital Management’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-25,000
Closed -$353K – 95
2020
Q2 		$353K Buy
+25,000
New +$316K 0.1% 79

Other funds holding PRVB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

DAFNA Capital Management's PRVB Position: Q3 2020 in Review

DAFNA Capital Management sold out of Provention Bio, Inc. Common Stock (PRVB) in Q3 2020, closing a stake of 25,000 shares — an estimated $353K sold.

DAFNA Capital Management first reported a position in PRVB in Q2 2020 and held it in 1 quarter. The position peaked at $353K in Q2 2020. 100 funds tracked by Wall St. Rank hold PRVB as of Q3 2020.

  • DAFNA Capital Management reported no remaining Provention Bio, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • DAFNA Capital Management sold 25,000 Provention Bio, Inc. Common Stock shares in Q3 2020, an estimated $353K.
  • DAFNA Capital Management first reported a position in Provention Bio, Inc. Common Stock in Q2 2020 and held it in 1 quarter.
  • DAFNA Capital Management's Provention Bio, Inc. Common Stock position peaked at $353K in Q2 2020.
  • 100 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q3 2020.

Based on DAFNA Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.